

Kflam

Ketorolac tromethamine

10 mg Tablet
30 mg/ml Injection

Description

Kflam (Ketorolac tromethamine) is a potent analgesic of the non-steroidal anti-inflammatory drug (NSAID). It inhibits the cyclooxygenase enzyme system and hence prostaglandin synthesis. Thus it gives minimal inflammatory effect at its analgesic effect. Kflam (Ketorolac tromethamine) is not an anesthetic agent and possesses no sedative or anxiolytic properties; therefore it is not recommended as a pre-operative medication for the support of anesthesia when these effects are required. It is not an opioid and has no known effects on opioid receptors.

Composition

Kflam Tablet : Each film coated tablet contains Ketorolac tromethamine USP 10 mg.

Kflam Injection: Each ampoule contains 1 ml sterile solution of Ketorolac Tromethamine USP 30 mg for intramuscular administration.

Indications and Uses

Relief of pain associated with surgical procedures such as major abdominal, orthopedic, dental or gynecological surgery; acute & chronic musculo-skeletal pain, renal colic, cancer pain.

Dosage and administration

Kflam (Ketorolac tromethamine) tablets are recommended for short-term use only (up to 7 days) and are not recommended for chronic use. 10 mg every 4 to 6 hours as required. Doses exceeding 40 mg per day are not recommended.

For patients receiving parenteral Ketorolac tromethamine, and who are converted to Ketorolac tromethamine oral tablets, the total combined daily dose should not exceed 90 mg (60 mg for the elderly, renally-impaired patients and patients less than 50 kg) and the oral component should not exceed 40 mg on the day the change of formulation is made. Patients should be converted to oral treatment as soon as possible.

Contraindications

Ketorolac tromethamine is contraindicated in patients having hypersensitivity to this drug or other NSAIDs and those patients in whom aspirin or other prostaglandin synthesis inhibitors induce allergic reactions. It is also contraindicated in a history of peptic ulcer or gastro-intestinal bleeding, moderate or severe renal impairment (serum creatinine > 160 micromol/l), a history of asthma.

Ketorolac tromethamine is contraindicated as prophylactic analgesia before surgery due to inhibition of platelet aggregation and is contraindicated intraoperatively because of the increased risk of bleeding. It is also contraindicated during pregnancy, delivery or lactation.

Precautions

Patients over the age of 65 years may be at a greater risk of experiencing adverse events than younger patients. Ketorolac tromethamine can cause gastro-intestinal irritation, ulcers or bleeding in patients with or without a history of previous symptoms.

Kflam

Ketorolac tromethamine

10 mg Tablet
30 mg/ml Injection

Bronchospasm may be precipitated in patients with a history of asthma.

Since Ketorolac tromethamine and its metabolites are excreted primarily by the kidney, patients with moderate to severe impairment of renal function (serum creatinine > 160 micromol/l), should not receive.

Fluid retention and oedema have been reported with the use of Ketorolac tromethamine.

Pregnancy and lactation

Safety in human pregnancy has not been established. Ketorolac tromethamine has been detected in human milk at low levels. Ketorolac tromethamine is therefore contraindicated during pregnancy, delivery or in mothers who are breast feeding.

Side effects

Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melaena, peptic ulcer, pancreatitis, anxiety, drowsiness, dizziness, headache, hallucinations, excessive thirst, inability to concentrate, insomnia, malaise, fatigue, pruritus, urticaria, skin photosensitivity, Stevens-Johnson syndrome, flushing, bradycardia, hypertension, palpitations, chest pain, infertility in female, dyspnoea, asthma, pulmonary oedema, fever.

Drug interactions

Ketorolac tromethamine should not be used with other NSAIDs or in patients receiving aspirin because of the potential for additive side effects. Care should be taken when administering Ketorolac tromethamine with anti-coagulants since co-administration may cause an enhanced anti-coagulant effect. Ketorolac tromethamine and other non-steroidal anti-inflammatory drugs can reduce the anti-hypertensive effect of beta-blockers and may increase the risk of renal impairment when administered concurrently with ACE inhibitors, particularly in volume depleted patients.

Caution is advised when methotrexate is administered concurrently, since some prostaglandin synthesis inhibiting drugs have been reported to reduce the clearance of methotrexate, and thus possibly enhance its toxicity.

Probenecid should not be administered concurrently with Ketorolac tromethamine because of increases in ketorolac plasma level and half-life.

Storage

Store in a cool dry place and away from light.

Keep out of the reach of children.

How supplied

Kflam Tablet : Box containing 2 x 10's tablets in blister pack.

Kflam Injection: Box containing 1x5's ampoules in blister pack



Manufactured by
Popular Pharmaceuticals Ltd. for
Apex Pharma Ltd.
Dhaka, Bangladesh